AOA is dedicated to the early diagnosis of cancer and has a pipeline focused on development of novel targets. The proprietary biomarker technology in glycolipids detects early-stage cancer in blood by quantifying circulating gangliosides across multiple cancers. The Tumor Ganglioside Matrix will be the next class of markers in early cancer detection.
AOA is committed to developing tools to help clinicians diagnose cancers early, when it matters most:
Our goal is to work closely with scientific innovators to bring their findings to market and make them widely available to impact clinical practice today and improve standard of care.